Spots Global Cancer Trial Database for Irinotecan in Treating Patients With Esophageal or Stomach Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Official Title: Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Study ID: NCT00003748
Interventions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or stomach cancer.
Detailed Description: OBJECTIVES: I. Determine the antitumor activity of irinotecan in patients with adenocarcinoma of the esophagus or gastric cardia. II. Evaluate the toxicities of this drug in this patient population. OUTLINE: This is a multicenter study. Patients receive irinotecan intravenous (IV) over 90 minutes once a week for 4 weeks followed by a 2 week rest period. Treatment continues in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months until death. PROJECTED ACCRUAL: A total of 18-32 patients will be accrued for this study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
St Jude Heritage Health Foundation, Fullerton, California, United States
Daniel Freeman Memorial Hospital, Inglewood, California, United States
UCLA - Antelope Valley Cancer Center, Lancaster, California, United States
Pacific Shores Medical Group, Long Beach, California, United States
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Office of Eddie Hu, M.D., Monterey Park, California, United States
Community Hospital of the Monterey Peninsula, Monterey, California, United States
Office of Jerome L. Rubin, Monterey, California, United States
Ventura County Hematology-Oncology Medical Group, Inc., Oxnard, California, United States
Wilshire Oncology Medical Center, Pomona, California, United States
Salinas Valley Memorial Hospital, Salinas, California, United States
Cancer Center of Santa Barbara, Santa Barbara, California, United States
Sansum Medical Clinic, Santa Barbara, California, United States
James L. Poth, M.D., Michael Alexander, M.D., Inc., Santa Cruz, California, United States
Marian Medical Center, Santa Maria, California, United States
Office of Marilou Terpenning, Santa Monica, California, United States
Office of Robert C. Klein, Santa Monica, California, United States
Dominican and Watsonville Community Hospital, Soquel, California, United States
Los Robles Regional Medical Center, Thousand Oaks, California, United States
Cancer Care Associates Medical Group, Torrance, California, United States
UCLA Cancer Center - Santa Clarita, Valencia, California, United States
Oncology Medical Center of North County, Vista, California, United States
Valley Hematology and Oncology, West Hills, California, United States
Cancer Care Consultants, Las Vegas, Nevada, United States
Contact Details
Name: Joel R. Hecht, MD
Affiliation: Jonsson Comprehensive Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
